The increase in survival rate was linked to the cancer containing a specific mutated gene known as PIK3CA, which is found in approximately one third of head and neck cancers.
It is hoped that despite the study focusing on head and neck cancer patients, that any cancer sufferer whose cancer contains the PIK3CA mutation gene could gain a more favourable outcome through the use of NSAIDs.